Glucose Transporter GLUT1 Expression and Clinical Outcome in Solid Tumors: a Systematic Review and Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Feb 11

PMID 28187435

Citations 93

Authors

Ji Wang

Chenyang Ye

Cong Chen

Hanchu Xiong

Binbin Xie

Jichun Zhou

Yongxia Chen

Shu Zheng

Linbo Wang

Affiliations

Soon will be listed here.

Abstract

Glucose transporter 1 (GLUT1), the uniporter protein encoded by the SLC2A1 gene, is a key rate-limiting factor in the transport of glucose in cancer cells, and frequently expressed in a significant proportion of human cancers. Numerous studies have reported paradoxical evidence of the relationship between GLUT1 expression and prognosis in solid human tumors. To address this discrepancy, we conducted a thorough search of Pubmed and Web of Science for studies evaluating the expression of GLUT1 and overall survival (OS) and disease-free survival (DFS) in patients with solid cancer from 1993 to April 2016. Data from published researches were extracted and computed into odds ratio (OR). A total of 26 studies including 2948 patients met our search criteria and were evaluated. Overexpression of GLUT1 was found to significantly correlate with poor 3-year OS (OR: 2.86; 95% CI, 1.90-4.32, P < 0.00001) and 5-year OS (OR: 2.52; 95% CI, 1.75-3.61, P < 0.00001) of solid tumors. Similar results were observed when analysis of DFS was performed. Subgroup analysis revealed that elevated GLUT1 expression was associated with worse prognosis of oral squamous cell carcinoma and breast cancer. Taken together, overexpression of GLUT1 is correlated with poor survival in most solid tumors, suggesting that the expression status of GLUT1 is a vital prognostic indicator and promising therapeutic target in solid tumors.

Citing Articles

Logic-gated approach for targeted delivery and site-selective activation of photothermal agents in precision cancer treatment.

Jiang C, Zhao Z, East A, Bandyopadhyay S, Jiang Z, Chan J Chem Sci. 2025; .

PMID: 39981039 PMC: 11837750. DOI: 10.1039/d4sc08228a.

Glucose Transporter 1 (GLUT1) Positivity in Ganglion Cysts: A Diagnostic Caveat Due to Overlap With Perineuriomas and Other Fibromyxoid Lesions.

Lazim A, Malik F, Cooper K Cureus. 2025; 17(1):e77142.

PMID: 39925503 PMC: 11804905. DOI: 10.7759/cureus.77142.

Linking microRNA to metabolic reprogramming and gut microbiota in the pathogenesis of colorectal cancer (Review).

Bin Wan Mohd Nor W, Kwong S, Fuzi A, Said N, Jamil A, Lee Y Int J Mol Med. 2025; 55(3).

PMID: 39820715 PMC: 11759585. DOI: 10.3892/ijmm.2025.5487.

Molecular exploration of natural and synthetic compounds databases for promising hypoxia inducible factor (HIF) Prolyl-4- hydroxylase domain (PHD) inhibitors using molecular simulation and free energy calculations.

Sayaf A, Kousar K, Suleman M, Albekairi N, Alshammari A, Mohammad A BMC Chem. 2024; 18(1):236.

PMID: 39593151 PMC: 11590322. DOI: 10.1186/s13065-024-01347-4.

Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.

Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y Mol Cancer. 2024; 23(1):261.

PMID: 39574178 PMC: 11580516. DOI: 10.1186/s12943-024-02165-x.

References

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Kang S, Chun Y, Hur M, Lee H, Kim Y, Hong S . Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res. 2002; 93(10):1123-8. PMC: 5926879. DOI: 10.1111/j.1349-7006.2002.tb01214.x. View

Younes M, Juarez D, Lechago L, Lerner S . Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001; 21(1B):575-8. View

Wardell S, Ilkayeva O, Wieman H, Frigo D, Rathmell J, Newgard C . Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol. 2008; 23(3):388-401. PMC: 2654518. DOI: 10.1210/me.2008-0179. View

Eckert A, Lautner M, Taubert H, Schubert J, Bilkenroth U . Expression of Glut-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol Rep. 2008; 20(6):1381-5. View

Haber R, Rathan A, Weiser K, Pritsker A, Itzkowitz S, Bodian C . GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998; 83(1):34-40. DOI: 10.1002/(sici)1097-0142(19980701)83:1<34::aid-cncr5>3.0.co;2-e. View

Basturk O, Singh R, Kaygusuz E, Balci S, Dursun N, Culhaci N . GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas. 2011; 40(2):187-92. PMC: 3164314. DOI: 10.1097/MPA.0b013e318201c935. View

Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A . Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 2000; 276(12):9519-25. DOI: 10.1074/jbc.M010144200. View

Kim B, Cho H, Chung J, Conway C, Ylaya K, Kim J . Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. J Transl Med. 2013; 11:185. PMC: 3750663. DOI: 10.1186/1479-5876-11-185. View

10.

Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G . Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2001; 60(2):162-9. DOI: 10.1159/000055314. View

11.

Sung J, Kim G, Lim S, Park Y, Kim Y . Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract. 2009; 206(1):24-9. DOI: 10.1016/j.prp.2009.07.018. View

12.

Cleven A, van Engeland M, Wouters B, de Bruine A . Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell Oncol. 2007; 29(3):229-40. PMC: 4617795. DOI: 10.1155/2007/945802. View

13.

Goos J, de Cuba E, Coupe V, Diosdado B, Delis-van Diemen P, Karga C . Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Ann Surg. 2015; 263(1):138-45. DOI: 10.1097/SLA.0000000000001109. View

14.

Cho H, Lee Y, Kim J, Chung J, Kim J . Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Cancer Invest. 2013; 31(9):607-15. DOI: 10.3109/07357907.2013.849722. View

15.

de Wit M, Jimenez C, Carvalho B, Belien J, Delis-van Diemen P, Mongera S . Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut. 2011; 61(6):855-64. DOI: 10.1136/gutjnl-2011-300511. View

16.

Lidgren A, Bergh A, Grankvist K, Rasmuson T, Ljungberg B . Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. BJU Int. 2007; 101(4):480-4. DOI: 10.1111/j.1464-410X.2007.07238.x. View

17.

Pardridge W, Boado R, Farrell C . Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J Biol Chem. 1990; 265(29):18035-40. View

18.

Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T . FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998; 39(10):1727-35. View

19.

Macheda M, Rogers S, Best J . Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2004; 202(3):654-62. DOI: 10.1002/jcp.20166. View

20.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View